Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Crohn's Disease~* Previous treatment failure to Infliximab (intolerance and/or no response)~Exclusion Criteria:~* Obstructive intestinal strictures~* Recent bowel resection~* Proctocolectomy or total colectomy~* Current total parenteral nutrition~* Short bowel syndrome~* All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active 1 (Type: EXPERIMENTAL): Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol
- Active 2 (Type: EXPERIMENTAL): Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol

Based on this trial design, predict the completion outcome and termination type (if applicable).